Literature DB >> 1618799

Thyroid hormone receptor mutants that cause resistance to thyroid hormone. Evidence for receptor competition for DNA sequences in target genes.

T Nagaya1, L D Madison, J L Jameson.   

Abstract

Several distinct mutations in the ligand-binding domain of the beta form of the thyroid hormone receptor have been reported in kindreds with the autosomal dominant syndrome of generalized resistance to thyroid hormone (GRTH). GRTH receptor mutants are functionally inactive but capable of inhibiting normal receptor function in transient expression studies. We examined the possibility that this dominant negative activity of the GRTH mutants involves competition for receptor binding to DNA. Mutations introduced into either the T3 ligand-binding domain (LBD) or into the DNA-binding domain (DBD) of the receptor eliminated the transcriptional activity of the receptor. In cotransfection experiments, the LBD mutants, but not the DBD mutants, inhibited the transcriptional activity of the normal receptor. The inhibitory activity of the LBD mutants was abolished by the introduction of an additional mutation into the DBD, suggesting that the DBD is required for dominant negative activity. A chimeric receptor, in which the DNA-binding domain of the thyroid hormone receptor was exchanged with the homologous region in the glucocorticoid receptor (GTG), was used to study thyroid hormone receptor competition for GTG interactions with thyroid receptor target sequences. In the absence of thyroid hormone, the normal thyroid hormone receptor inhibited dexamethasone stimulated transcription by GTG. The transcriptional activity of GTG was also inhibited by the LBD mutants but not by a DBD mutant of the thyroid hormone receptor. These results indicate that the thyroid hormone receptor mutations that occur in GRTH compete with normal receptors at DNA-binding sites in target genes to block normal receptor function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618799

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome.

Authors:  T Nagaya; M Fujieda; G Otsuka; J P Yang; T Okamoto; H Seo
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Thyroid-hormone-dependent negative regulation of thyrotropin beta gene by thyroid hormone receptors: study with a new experimental system using CV1 cells.

Authors:  Keiko Nakano; Akio Matsushita; Shigekazu Sasaki; Hiroko Misawa; Kozo Nishiyama; Yumiko Kashiwabara; Hirotoshi Nakamura
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

3.  A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.

Authors:  T N Collingwood; R Wagner; C H Matthews; R J Clifton-Bligh; M Gurnell; O Rajanayagam; M Agostini; R J Fletterick; P Beck-Peccoz; W Reinhardt; G Binder; M B Ranke; A Hermus; R D Hesch; J Lazarus; P Newrick; V Parfitt; P Raggatt; F de Zegher; V K Chatterjee
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

4.  The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms.

Authors:  H W Chen; M L Privalsky
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

5.  Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.

Authors:  C A Meier; C Parkison; A Chen; K Ashizawa; S C Meier-Heusler; P Muchmore; S Y Cheng; B D Weintraub
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 6.  Germline and somatic thyroid hormone receptor mutations in man.

Authors:  P M Yen; S Y Cheng
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

7.  Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta 1 receptors.

Authors:  R Wong; X G Zhu; M A Pineda; S Y Cheng; B D Weintraub
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

8.  Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes encoding beta-oxidation enzymes: cross talk between peroxisome proliferator and T3 signaling pathways.

Authors:  R Chu; L D Madison; Y Lin; P Kopp; M S Rao; J L Jameson; J K Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

9.  Positive and negative modulation of Jun action by thyroid hormone receptor at a unique AP1 site.

Authors:  G Lopez; F Schaufele; P Webb; J M Holloway; J D Baxter; P J Kushner
Journal:  Mol Cell Biol       Date:  1993-05       Impact factor: 4.272

10.  Mutations of CpG dinucleotides located in the triiodothyronine (T3)-binding domain of the thyroid hormone receptor (TR) beta gene that appears to be devoid of natural mutations may not be detected because they are unlikely to produce the clinical phenotype of resistance to thyroid hormone.

Authors:  Y Hayashi; T Sunthornthepvarakul; S Refetoff
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.